Follow
The FDA has approved Merck's sotatercept for pulmonary arterial hypertension.
I wrote about this activin receptor IIA (TGF-β family member) & human immunoglobulin IgG1 Fc domain fusion protein at the end of 2022:
"Studies of familial disease have found that over 70% of cases have mutations in the BMPR2 gene, which encodes the TGF-β (transforming growth factor-β) family member BMPR-II (bone morphogenetic protein type II receptor), or in genes encoding molecules in the BMPR-II signaling pathway. Mutations in the BMPR-II pathway are also seen in idiopathic cases, and patients with BMPR2 mutations have an earlier age of onset and a more severe course of the disease."
